Levosert One

Levonorgestrel, the active ingredient in Levosert One, is a progestin presented as a 52 mg intrauterine system for intrauterine use. It provides long‑acting reversible contraception and can be used to treat heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Levosert One as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levonorgestrel delivered via Levosert One is used within the hormonal contraceptive pathway to prevent pregnancy and manage menstrual disorders. - Contraception (long‑acting reversible contraceptive): provides up to three years of reliable pregnancy prevention. - Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with excessive bleeding. - Endometrial protection in estrogen therapy: helps prevent estrogen‑induced endometrial proliferation when combined with systemic estrogen.

Levosert One may be associated with a range of adverse reactions.

Common Side Effects: - Irregular bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal cramping - Device expulsion or displacement - Vaginal discharge - Headache or mild nausea

Serious or Rare Side Effects: - Uterine perforation during insertion - Pelvic inflammatory infection - Ectopic pregnancy if contraception fails - Severe allergic reaction (anaphylaxis) - Hormonal side effects such as severe depression or mood changes

Before insertion and during use, certain precautions should be observed. - Pregnancy testing: confirm a negative pregnancy test prior to insertion. - Uterine abnormalities: evaluate for fibroids, septa, or other malformations. - Active infection: screen for pelvic inflammatory disease and treat before placement. - Breastfeeding: discuss benefits and risks with the patient. - Follow‑up removal: schedule device removal or replacement at the end of the intended duration. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from an intrauterine system has limited systemic interactions, but certain drugs may affect its efficacy.

Major Interactions (Avoid): - Rifampicin and other strong CYP3A4 inducers: may markedly reduce contraceptive effectiveness. - Antiretroviral protease inhibitors (e.g., ritonavir): can alter hormone levels and compromise efficacy. - Ketoconazole and other potent antifungal agents: may decrease levonorgestrel activity.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline): minimal effect but monitor for breakthrough bleeding. - St. John’s wort (hypericum perforatum): may modestly reduce hormone levels. - Combined estrogen‑containing therapies: may increase risk of thromboembolic events; monitor patient closely.